** Chimeric Therapeutics CHM.AX falls 7.7% to A$0.006, lowest since February 26
** Biotech firm says it intends to raise up to A$3.2 mln ($1.99 mln) at A$0.005, a discount of 28.6% to last close
** Adds funds will used for continued development of co's CDH17 Phase 1/2 clinical trial
** Stock down 14.3% YTD
($1 = A$1.6116)
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.